Home Online Features Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Neurizon’s NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Hand-out
Press Releases
Neurizon Therapeutics Limited  
November 19, 2024

Neurizon’s NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Highlights:

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social